Human Xt-M (HUMX.M) AI Stock Analysis

• Market Cap: ₪6.29M
• Dividend Yield: N/A
• Average Volume (3M): 50.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.21
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 21
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 26,756,048
• 10 Day Avg. Volume: 22,744
• 30 Day Avg. Volume: 50,094
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 23.00 ▼(-10.85% Downside)

The score is held down primarily by weak financial performance, including a major 2024 revenue decline, negative gross profit, large losses, and persistent cash burn despite low debt. Technicals offer only modest support via short-term strength, while valuation is constrained by a loss-making profile (negative P/E) and no dividend yield support.

Positive Factors

Very low leverage

Zero reported debt materially reduces refinancing and interest-rate risk and preserves financial optionality. Over a 2–6 month horizon this strengthens the firm's ability to negotiate restructuring, access capital markets if needed, and prioritize operational fixes without immediate debt-service pressure.

Improving cash burn trend

A reduction in peak cash burn signals management has taken measures to slow outflows, which can extend runway and reduce near-term financing needs. If sustained, this structural improvement supports the firm’s ability to execute turn-around actions and stabilise operations over the medium term.

Historical revenue growth prior to 2024

Prior growth in 2022–2023 demonstrates the company has been able to scale demand and suggests some product-market fit or addressable market. That prior traction provides a foundation for recovery initiatives and strategic redeployment of resources if underlying market conditions or execution improve.

Negative Factors

Sharp 2024 revenue collapse and negative gross profit

A ~74% revenue drop paired with negative gross profit indicates unit economics are broken and costs exceed sales. Structurally, this undermines margin sustainability and means simple volume recovery alone won’t restore profitability; durable remediation requires major cost or business-model changes.

Persistent negative operating and free cash flow

Consistent negative OCF and FCF show the business systematically consumes cash, necessitating ongoing funding or dilution. This pattern constrains strategic flexibility, increases refinancing and equity-issuance risk, and poses a sustained threat to continuity absent durable cash-generation improvements.

Equity erosion and deeply negative returns

Significant equity contraction and deeply negative ROE reflect cumulative losses that deplete the capital base. This structural deterioration heightens dilution risk, weakens creditor and investor confidence, and makes raising capital on reasonable terms harder, impairing long-term viability.

Human Xt-M Business Overview & Revenue Model

Company Description

Human Xtensions Ltd. develops, manufactures, markets and sells a modular medical device for minimally invasive surgical operations. It offers HandX, a handheld electromechanical device for use in laparoscopic procedures; Fenestrated Grasper; Monopolar Hook; and Needle Holder. The company was incorporated in 2012 and is based in Netanya, Israel.

How the Company Makes Money

Human Xt (HUMX) generates revenue through the sale of its smart wearable devices and augmented reality applications, which are available to both individual consumers and corporate clients. The company also offers AI-driven software solutions on a subscription basis, providing continuous updates and support. Key revenue streams include direct product sales, subscription fees for software services, and partnerships with technology firms to integrate HUMX's solutions into broader ecosystems. Additionally, strategic alliances with enterprise clients in various industries allow the company to create customized solutions that cater to specific business needs, thereby enhancing its earnings.

Human Xt-M Financial Statement Overview

Summary

Income statement and cash flow are very weak: 2024 revenue fell sharply (~74% YoY) with negative gross profit and large losses, while operating and free cash flow remain persistently negative with substantial burn. The balance sheet benefits from minimal debt, but materially reduced equity and deeply negative returns highlight ongoing financing risk.

Income Statement

Revenue has been highly volatile, with a sharp decline in 2024 (down ~74% YoY) after growth in 2022–2023. Profitability is weak and worsening: 2024 produced negative gross profit (implying costs exceeded revenue) and very large operating and net losses, with net margin deteriorating materially versus prior years. While losses have been persistent across the full period, the step-down in revenue and margins in 2024 is a clear near-term negative.

Balance Sheet

Leverage is very low—total debt is reported at zero in 2024 and was modest in prior years—reducing financial risk from interest and refinancing pressure. However, equity has contracted dramatically over time (from much higher levels in 2020–2021 to a low level in 2024), consistent with sustained losses and potential dilution/erosion of capital. Returns on equity are deeply negative, signaling that the current capital base is not generating profits.

Cash Flow

Cash burn remains heavy and persistent: operating cash flow and free cash flow are negative every year shown, and 2024 free cash flow declined further (roughly -24% YoY). Losses are broadly mirrored by cash outflows (free cash flow is about in line with net loss), which suggests limited accounting-to-cash uplift. The main positive is that cash burn improved versus the very worst years (e.g., 2021–2022), but 2024 still reflects substantial funding needs.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Human Xt-M Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 25.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:HUMX.M, the sentiment is Positive. The current price of 25.8 is above the 20-day moving average (MA) of 19.45, above the 50-day MA of 18.83, and below the 200-day MA of 26.65, indicating a neutral trend. The MACD of 1.30 indicates Negative momentum. The RSI at 75.09 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:HUMX.M.

Human Xt-M Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
HUMX.M	46 Neutral	₪6.29M	-0.67	―	―	―	―